#USA #New York #Class Action #Pomerantz Law #Applied Therapeutics

Pomerantz Law Firm's Class Action Alert on Applied Therapeutics, Inc.

Pomerantz LLP, a well-known law firm in corporate litigation, has recently announced a significant class action lawsuit against Applied Therapeutics, Inc. (NASDAQ: APLT). This lawsuit centers on allegations of securities fraud and other unlawful business practices involving the firm and some of its officers.

Background of the Case

As an investor in Applied Therapeutics, you may be feeling concern after the company faced serious setbacks regarding its drug application for govorestat, aimed at treating Classic Galactosemia, a rare genetic disorder. On November 27, 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the company, stating that they could not approve the New Drug Application (NDA) due to clinical application deficiencies. Following this announcement, shares of Applied Therapeutics dropped significantly, falling $1.64, or approximately 16.06%.

Just days later, on December 2, 2024, Applied Therapeutics disclosed that the FDA had sent them a warning letter referring to issues in their clinical trials that were linked to the CRL. This letter mentioned problems concerning electronic data capture and a dosing error in trial phases, which further depressed the stock's value by 26.29%, causing it to close at $1.29 per share by December 5, 2024. Investors who have suffered losses during this period are now urged to take action.

Important Deadlines

Investors interested in joining the class action lawsuit have until February 18, 2025, to notify the court of their intent to become Lead Plaintiffs. This opportunity emphasizes the urgency for shareholders who purchased or acquired Applied Therapeutics securities during the specified Class Period.

Pomerantz encourages investors from the class to reach out for more information. Interested parties can contact Danielle Peyton by email at [email protected] or by phone at 646-581-9980. When contacting via email, including relevant details such as the number of shares purchased can expedite the process.

The Legacy of Pomerantz LLP

Founded by Abraham L. Pomerantz, known for pioneering securities class action law, Pomerantz LLP has maintained a reputation for fighting for the rights of investors against securities fraud and corporate misconduct. With more than 85 years of experience, they have secured billions in damages for class members who have suffered actionable harms in corporate environments.

In this ongoing saga of Applied Therapeutics, affected shareholders should remain vigilant and proactive. It is essential for all investors to stay informed of any deviations in corporate conduct that might impact stock performance, especially in such tumultuous times.

For ongoing updates about this lawsuit and other securities issues, visit Pomerantz's official website. Don't miss your chance to seek justice and recompense for your investments! Stay tuned for more developments from the firm as they continue their efforts in advocacy for shareholders' rights.

Conclusion

With the potential for significant recovery through this class action lawsuit, affected shareholders must take immediate action to safeguard their interests. Reaching out to legal counsel and being part of a class can lead to restitution for losses incurred due to corporate mismanagement at Applied Therapeutics. Keep your eyes on the deadlines, and don't hesitate to get involved in this pivotal legal battle.